Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Rhea-AI Summary

Larimar Therapeutics, Inc. will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York from November 6-7, 2023. The fireside chat will take place on November 7, 2023, from 1:10 - 1:40 PM ET. A replay of the chat will be available on Larimar's website for 30 days.

BALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5^th Annual Inflammation, Neurology & Immunology Conference, taking place in New York, NY from November 6 - 7, 2023.

Details on the fireside chat can be found below.

Date: Tuesday, November 7, 2023
Time: 1:10 – 1:40 PM ET
Webcast Link: https://guggenheim.metameetings.net/events/ini23

Following the conclusion of the fireside chat, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:                                                        
Joyce Allaire                                                                
LifeSci Advisors                                                        
jallaire@lifesciadvisors.com                                                 
(212) 915-2569

Company Contact:
Michael Celano        
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
                                                

 

FAQ

What is Larimar Therapeutics, Inc.?

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.

What is the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference?

The Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference is an event where industry professionals gather to discuss advancements and developments in the field of inflammation, neurology, and immunology.

When will Larimar Therapeutics participate in the fireside chat?

Larimar Therapeutics will participate in the fireside chat on Tuesday, November 7, 2023, from 1:10 - 1:40 PM ET.

Where can I watch the fireside chat?

The fireside chat can be watched through the webcast link: https://guggenheim.metameetings.net/events/ini23.

Will there be a replay of the fireside chat?

Yes, a replay of the fireside chat will be available on Larimar's website for 30 days.